NCT00379080 2017-04-07Tandutinib in Treating Patients With Recurrent or Progressive GlioblastomaNational Cancer Institute (NCI)Phase 1/2 Completed60 enrolled 22 charts
NCT00297921 2013-11-06A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction TherapyMillennium Pharmaceuticals, Inc.Phase 1/2 Withdrawn